Siemens Healthineers AG

Siemens Healthineers AG

48.26
USD
-0.25
(-0.52%)
2.27EPS
19.95P/E
50.09BMarket Cap
Feb 04Next Earn
Siemens Healthineers AG
OTC:SEMHF
(OTC Markets)

Recent

price

48.26

P/E

ratio

19.95

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
EUR
12.94
13.55
13.68
13.43
14.53
14.43
16.37
19.34
19.37
20
- -
21.11
21.13
Revenue per Share
1.28
1.31
1.38
1.27
1.57
1.41
1.57
1.82
1.35
1.74
- -
1.98
1.98
Basic EPS, GAAP
1.55
1.43
1.04
1.07
1.04
1.37
2.05
1.47
1.14
1.9
- -
2.18
2.19
Free Cash Flow per Basic Share
0.15
0.38
0.35
1.01
0.7
0.8
0.78
0.85
0.95
0.95
- -
1
- -
Dividend per Share
3.69
2.47
3.28
8.66
9.78
11.64
14.54
17.72
16.2
16.26
- -
17.74
17.74
Book Value per Share
-6.18
-7.41
-6.24
-1.09
-0.4
1.44
-8.37
-7.09
-6.96
-5.83
- -
-3.66
-3.66
Tangible Book Value per Share
1,000
1,000
1,000
1,000
999
1,002
1,100
1,123
1,119
1,118
1,123
1,119
1,118
Basic Weighted Avg Shares
12,936
13,547
13,677
13,429
14,518
14,460
17,997
21,714
21,680
22,363
- -
23,630
23,630
Sales/Revenue/Turnover
15.17
15.63
16.25
14.6
15.81
13.44
14.27
13.47
9.84
12.56
- -
13.52
13.53
Operating Margin (%)
563
591
572
530
620
815
1,039
1,343
1,557
1,223
- -
1,187
1,187
Depreciation Expense
1,277
1,311
1,379
1,265
1,567
1,411
1,727
2,038
1,509
1,942
- -
2,214
2,213
Net Income, GAAP
31.13
30.76
29.39
28.63
27.68
27.23
27.37
26.64
20.9
22.35
- -
22.35
22.36
Effective Tax Rate (%)
9.87
9.68
10.08
9.42
10.79
9.76
9.6
9.39
6.96
8.68
- -
9.37
9.37
Profit Margin (%)
-6,092
-1,456
-2,316
1,896
2,174
2,979
759
1,355
696
2,870
- -
2,431
2,431
Working Capital
14
14
15
17
61
314
457
461
436
513
- -
589
589
LT Debt
3,728
2,505
3,289
8,676
9,782
12,511
16,339
19,852
18,133
18,248
- -
19,917
19,917
Total Equity
- -
44.67
49.36
21.79
16.92
11.98
11.95
10.92
8.21
11.06
- -
- -
- -
Return on Invested Capital (%)
- -
45.73
52.36
23
17.54
12.69
11.79
11.22
8.79
12.14
- -
- -
- -
Return on Capital (%)
- -
42.56
47.94
21.19
17.01
12.67
11.99
11.27
7.96
10.71
- -
- -
- -
Return on Common Equity (%)

Capital Structure

EUR

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
318
256
277
LT Borrowings
- -
- -
- -
LT Finance Leases
503
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,119
1,119
1,119
Market Capitalization
41,123
39,171
44,192

Working Capital

EUR

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
14,179
14,957
15,651
Cash, Cash Equivalents & STI
2,298
2,753
2,955
Accounts Receivable, Net
4,585
4,515
4,971
Inventories
4,463
4,723
4,522
Total Current Liabilities
12,885
12,874
13,220
Payables & Accruals
- -
- -
- -
ST Debt
318
256
277
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,176
5,435
5,423
6,329
22,363
2025
5,482
5,909
5,662
- -
- -
2026
5,402
5,680
5,764
6,784
23,630

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.39
0.38
0.42
0.55
1.74
2025
0.42
0.47
0.49
- -
- -
2026
0.4
0.45
0.6
0.53
1.98

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.95
- -
0.95
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
1
Business
Siemens Healthineers AG (SHL.DE) develops, manufactures and markets diagnostic and therapeutic products and services for healthcare providers worldwide; core offerings span Imaging with magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging and ultrasound devices; Diagnostics encompassing in-vitro testing including clinical chemistry analyzers, immunoassay systems, hematology, coagulation, urinalysis, blood gas analysis and molecular diagnostics; Varian segment providing multi-modality cancer care technologies, radiation oncology solutions and integrated digital workflows; Advanced Therapies featuring angiography systems, mobile C-arms and image-guided therapies; plus digital health services such as artificial intelligence in radiology, health data analytics, telemedicine platforms and workflow optimization tools. The company operates globally across Americas, Europe, Asia-Pacific, Middle East and CIS regions through approximately 72,000 employees, generating around €22 billion in revenue in fiscal year 2024 with key segments including Imaging at €11.8 billion, Diagnostics at €4.4 billion, Varian at €3.8 billion and Advanced Therapies at €2 billion. Headquartered in Forchheim near Erlangen, Germany with registered office in Munich, Siemens Healthineers traces its roots to 1847 as part of Siemens AG, which retains a 75% stake following the 2017 spin-off and 2018 IPO; it serves hospitals, clinics, laboratories and oncology centers with solutions influencing nearly three-quarters of critical clinical decisions. Recent developments include the December 2024 completion of its €200 million-plus acquisition of Novartis' Advanced Accelerator Applications Molecular Imaging business, adding 13 European radiopharmacies in France, Spain, Portugal, Italy and Germany plus a workforce of 420 to bolster PETNET Solutions' network for diagnostic radiopharmaceuticals in oncology, neurology and cardiology; a May 2025 announcement of $150 million U.S. investments in production expansion and job creation; and ongoing emphasis on AI integration and theranostics to drive precision medicine and growth in the €500 million PET sector projected to triple by 2033.

Company News

  • Siemens Healthineers AG (SMMNY) Q4 2026 Earnings Call Transcript

  • Siemens Healthineers to Rebrand as Healthineers as Diagnostics Carve-Out Begins

  • Siemens Healthineers starts carve-out of diagnostics business

  • Siemens Healthineers expects FY2027 revenue growth of 4%-5%

  • Siemens Healthineers AG (SMMNY) Discusses Foreign Exchange and Tariff Impacts on Q4 Revenue and Earnings Prepared Remarks Transcript

  • Sun Nuclear Announces Validated Adaptive QA Solution in Support of New Radiotherapy System, Accela, by Siemens Healthineers

  • Siemens Healthineers (OTCMKTS:SEMHF) Stock Price Down 0.4% – Here’s What Happened

  • Siemens Healthineers (OTCMKTS:SMMNY) Stock Price Down 0.2% – Here’s What Happened

  • Siemens Healthineers: Successful Investment, Updating For H2 2026

  • Siemens Healthineers AG (SMMNY) Q3 2026 Earnings Call Transcript

  • Siemens Healthineers Cuts Revenue Outlook on Diagnostics Weakness

  • Siemens Healthineers cuts revenue forecast citing diagnostics weakness

  • Siemens Healthineers AG (SMMNY) Discusses Q3 Pre-Close Updates: Foreign Exchange and Tariff Impacts on Revenue and Earnings Prepared Remarks Transcript

  • AiM Medical Robotics Announces Collaboration Agreement with Siemens Healthineers to Advance MRI-Guided Robotic Neurosurgery

  • Siemens Healthineers: Update Post The Carve-Out Announcement

  • Siemens Healthineers cuts 2026 outlook

  • Siemens Healthineers: Razor-And-Blades Model On A China-Driven Dip

  • CDC HoST-TT Certification for Siemens Healthineers Total Testosterone Test Expands Patient Access to Gold Standard Equivalent Results

  • Siemens Healthineers AG (OTCMKTS:SMMNY) Receives Average Rating of “Buy” from Brokerages

  • Siemens plans shareholder vote on Siemens Healthineers spin-off in February 2027